The New Treatment Innovation Grant supports Australian researchers in developing early-stage, innovative ideas to improve pancreatic cancer treatments, diagnostics, and care quality, with a focus on generating preliminary data, answering key feasibility questions, and accelerating research translation.

These projects should explore innovative solutions that have the potential to significantly advance the therapeutic field.

The New treatment Innovation Grant will provide funding to Australian researchers to:

• Carry out projects at an early stage that will accelerate innovation of treatments, diagnostics or quality (including standard of care) to pancreatic cancer patients
• Support innovative ideas that have the potential to impact treatment or diagnostics, but may not have extensive preliminary supporting data
• Answer key feasibility and proof-of-concept questions and arrive at critical project inflection points in an accelerated time frame
• Support established and/or early career researchers to develop preliminary data and attract additional funding in subsequent years
• Accelerate research translation

Criteria for funding:

• Applications should demonstrate solid rationale and extensive planning
• Proof-of-concept or exploratory data to demonstrate the feasibility and rationale for your research questions should be detailed sufficiently
• Applicants must disclose any potential overlap with other current or pending research funding
• Where applications have multiple AI's, the role of each co-investigator must be outlined and justified
• Only one application per institution may be submitted for each scheme
• International collaborations are encouraged if the PI is located in Australia

Pankind will only fund projects where all of the following conditions are met:

1. Only one application per institution may be submitted for each grant category.
2. The administering institution agrees to the terms and conditions of funding as outlined in Pankind's Research Funding Agreement. Please note amendments to the agreement terms are generally not accepted and institutional representatives must review the agreement prior to submission.
   Please Note: Their Funding Agreement is undergoing revisions. The current version will be available shortly. Until then, the previous version remains available for reference
3. The grant applicant (Principal Investigator) is based in Australia and the administering institution is an Australian organisation.
4. The applicant is named as Principal Investigator on no more than one application across all grant categories in the same round.
5. The applicant and all research team members are funded at a maximum of 1.0 full-time equivalent across the project.
6. Applicants who currently hold a Pankind grant as Principal Investigator must have that grant concluding within the current calendar year. Pankind reserves the right to alter or withdraw an offer of award where the requirements of a currently held grant have not been fulfilled.
7. Biotechnology, pharmaceutical, and other commercial entities are eligible to apply; however, Pankind reserves the right to vary the terms of funding for successful commercial applicants.
8. Adhere to the Permitted Use of Funds (see Policies and Procedures tab) within budgets.
9. Where the project involves human biospecimens or data, applicants must provide a letter of support from an appropriate and accessible repository or collection at the time of application. Ethics and governance arrangements must be clearly outlined, including the current status of approvals and a defined pathway to achieving any outstanding requirements before the project commences.

• Phone: (02) 7207 6970
• Email: grants@pankind.org.au